Brought to you by

Renova gets exclusive license to gene portfolio from RFD
17 Oct 2016
Executive Summary
The Research Development Foundation (RDF) licensed Renova Therapeutics exclusive global rights to a portfolio of urocortin and stresscopin genes, and select peptides and proteins.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com